Skip to main content
. 2022 Nov 11;13:1034253. doi: 10.3389/fimmu.2022.1034253

Figure 2.

Figure 2

The pooled CR (A) and ORR (B) in patients with R/R B-NHL receiving copanlisib monotherapy were significantly higher than those receiving combination therapy, including copanlisib plus rituximab, while results for pooled SDR (C) and PDR (D) were reversed between the two groups.